Comment: AstraZeneca-Alexion US clearance shows large pharma deals can still avoid deep probes
The clearance of AstraZeneca’s proposed acquisition of Alexion by the US Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy investigations in the Biden administration despite promises for...To view the full article, register now.
Already a subscriber? Click here to view full article